BioSpace News Archive

Business

Arcturus Rockets on New Hep B RNA Deal With Johnson & Johnson

Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.

October 19, 2017
·
2 min read
·
Alex Keown
BioMidwest

Weeks After Buying ReShape Medical for $38M, EnteroMedics Bags $61M

EnteroMedics recently filed with the SEC that it had raised $61M in a new equity financing round. There were 13 anonymous investors.

October 19, 2017
·
3 min read
·
Mark Terry
Business

AstraZeneca Inks R&D Deal With Ramaswamy’s Roivant for Hush-Hush Indication

Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra.

October 19, 2017
·
3 min read
·
Mark Terry
Business

Bay Area’s Intuitive Surgical Buys NC Facility Very Close to Rival TransEnterix

The new acquisition joins a smaller facility Intuitive has in the region at N.C. State University’s Centennial Campus.

October 19, 2017
·
1 min read
Prenetics Of Hong Kong Raises $40 Million For Individual DNA Testing

Prenetics Limited raised $40 million to expand its pan-Asia DNA testing service aimed at individuals.

October 19, 2017
·
1 min read
FDA

Novartis Has Set a Tricky Precedent in Gene Therapy

A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.

October 19, 2017
·
5 min read
·
Karl Thiel
Deals

WuXi AppTec Scoops Up Texas-Based Global Clinical Trial CRO

WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.

October 19, 2017
·
1 min read
Drug Development

$710M Gamble Fails as Celgene Terminates Two Phase III Trials

Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710M deal three years ago following an interim data analysis.

October 19, 2017
·
2 min read
·
Alex Keown
Drug Development

DURECT Stock Plunges as Pain Med Fails Phase III

DURECT’s Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.

October 19, 2017
·
2 min read
·
Mark Terry